H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Copenhagen Studies on Asthma in Childhood.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Copenhagen Studies on Asthma in Childhood
ClinicalTrials.gov Identifier:
NCT01012557
First received: November 10, 2009
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

Pregnant women are at particular risk during the imminent H1N1v influenza pandemic. The new H1N1v virus requires urgent political and medical decisions on vaccination strategies in order to minimize severe disease and death from this pandemic. However, there is a lack of evidence to build such decisions upon. A vaccine will be provided in the fourth quarter of 2009, but there is little knowledge on the immunogenicity. Particularly its clinical effectiveness and duration of immunity in pregnant women and their newborn infants is unknown. Therefore, it will be important to study the optimal vaccination regimens with respect to dosing and use of adjuvant to decide future health policies on vaccination of pregnant women. We have a unique possibility to study these aspects of H1N1v infection in pregnant women in our ongoing unselected, prospective, birth-cohort study recruiting 800 pregnant mothers between Q1- 2009 and Q4-2010. Pregnant women from East-Denmark are being enrolled during the 2nd trimester and their infant will undergo a close clinical follow-up. The H1N1v pandemic is expected to reach Denmark Q4-2009. The timing of this enrollment and the imminent pandemic allows for an "experiment of nature" whereby the first half of the mothers completes pregnancy before the H1N1v pandemic. The other half of this cohort will be pregnant while H1N1v is prevalent in the community and will require H1N1v vaccination. The aim of this randomized, controlled, trial is to compare and evaluate the dose-related immune protection conferred by vaccine and adjuvant (Novartis vaccine Focetria) in pregnant women and non-pregnant women. In addition the protocol will assess the passive immunity conferred to the newborn from these vaccine regimes. The study will provide evidence-based guidance for health policies on vaccination for the population of pregnant women during future H1N1v pandemics.


Condition Intervention
H1N1v Influenza
Biological: Focetria

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza AH1N1v Vaccination in Pregnant Women

Resource links provided by NLM:


Further study details as provided by Copenhagen Studies on Asthma in Childhood:

Primary Outcome Measures:
  • Day 22/Day 1, and at all the other relevant time points to assess persistence/Day 1 geometric mean ratio (GMR) of HI [ Time Frame: Day 1, Day 22 ] [ Designated as safety issue: No ]
  • Geometric mean HI titer (GMT) on Day 1, Day 22, and at all the other relevant time points to assess persistence. [ Time Frame: Day 1, Day 22 ] [ Designated as safety issue: No ]
  • Percentage of subjects achieving a seroconversion or a significant increase (defined as: HI ≥1:40 for subjects negative at baseline [<1:10]; a minimum 4-fold increase in HI titer for subjects positive at baseline [HI≥1:10]) [ Time Frame: Day 1, Day 22 ] [ Designated as safety issue: No ]
  • Percentage of subjects with a HI titer ≥1:40 (i.e. seroprotection) on Day 1, Day 22, and at all the other relevant time points to assess persistence [ Time Frame: Day 1, Day 22 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The safety of the study vaccines will be assessed based on number of subjects exposed to study vaccines with reported selected adverse events per vaccine group. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • The outcomes of pregnancies will be categorized as normal, abnormal or therapeutic/elective termination [ Time Frame: duration of pregnancy ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 600
Study Start Date: November 2009
Estimated Study Completion Date: November 2012
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant Biological: Focetria
7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
Active Comparator: Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant Biological: Focetria
3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
Active Comparator: Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted Biological: Focetria
15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
Active Comparator: Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant Biological: Focetria
7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy pregnant and non pregnant women living in Eastern Denmark
  • Fluent in Danish

Exclusion Criteria:

  • Heart disease, endocrine disease, tuberculosis and sarcoidosis.
  • History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, to any excipients, and to eggs (including ovalbumin), and chicken proteins.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01012557

Locations
Denmark
COPSAC
Gentofte/Copenhagen, Denmark, 2620
Næstved Hospital, Pediatric Department
Næstved, Denmark, 4700
Sponsors and Collaborators
Copenhagen Studies on Asthma in Childhood
Novartis
  More Information

No publications provided by Copenhagen Studies on Asthma in Childhood

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Copenhagen Studies on Asthma in Childhood
ClinicalTrials.gov Identifier: NCT01012557     History of Changes
Other Study ID Numbers: H1N1v
Study First Received: November 10, 2009
Last Updated: June 18, 2012
Health Authority: Denmark: Danish Medicines Agency
Denmark: Ethics Committee
Denmark: Data Agency

Keywords provided by Copenhagen Studies on Asthma in Childhood:
H1N1v
vaccine
pregnant
women
Assess whether the adjuvanted vaccine offers a meaningful benefit in pregnant women in terms of immune response over the non-adjuvanted vaccine.
Assess the persistence of immune response over a 15 month time period after one single vaccination of the pregnant mother.
Assess whether the immune response to H1N1 in pregnant women is different from that of non-pregnant women of similar age.
Gain insight on safety of the Novartis egg-based MF59 adjuvanted H1N1 vaccine Focetria in pregnant women and their babies.
Assess the maternally transferred specific antibodies against H1N1v in the newborn
Passive immunity transferred to the infant.

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 26, 2014